MediWound to Report Second Quarter 2025 Financial Results
MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, will release its Q2 2025 financial results on Thursday, August 14, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, will release its Q2 2025 financial results on Thursday, August 14, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and provide corporate updates.
Investors can access the call via multiple channels including toll-free numbers for US and Israel, and an international dial-in. A webcast replay will be available in the Investors section of MediWound's website after the call.
Details
News Market Reaction – MDWD
On Aug 4, the day this news came out, MDWD closed 0.86% below the previous close.
Data tracked by StockTitan Argus for the Aug 4 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MediWound to Report Second Quarter 2025 Financial Results
Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time
YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025.
Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates.
Dial-in and call details are as follows:
Conference Call & Webcast Details
Toll-Free: 1-844-676-8833
Israel: 1-80-9212373
International: 1-412-634-6869
Webcast: Webcast Link
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.
For more information visit www.mediwound.com and follow us on LinkedIn.
MediWound Contacts:
Hani Luxenburg Daniel Ferry
Chief Financial Officer Managing Director
MediWound Ltd. LifeSci Advisors, LLC
ir@mediwound.com daniel@lifesciadvisors.com
Media Contact:
Ellie Hanson
FINN Partners for MediWound
ellie.hanson@finnpartners.com
+1-929-588-2008
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.